(VIANEWS) – CONTEXTVISION (CONTX.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CONTEXTVISION (CONTX.OL) | kr8.00 | 3.49% | 61.1% |
| EQUASENS (EQS.PA) | €75.90 | 1.4% | 28.59% |
| BIOMERIEUX (BIM.PA) | €93.70 | 0.89% | 12.95% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CONTEXTVISION (CONTX.OL)
3.49% Forward Dividend Yield and 61.1% Return On Equity
ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and Rivent 3D, an image enhancement product for 3D ultrasound. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI. The company was founded in 1983 and is headquartered in Stockholm, Sweden.
Earnings Per Share
As for profitability, CONTEXTVISION has a trailing twelve months EPS of kr0.45.
PE Ratio
CONTEXTVISION has a trailing twelve months price to earnings ratio of 17.78. Meaning, the purchaser of the share is investing kr17.78 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.1%.
Moving Average
CONTEXTVISION’s worth is below its 50-day moving average of kr8.36 and below its 200-day moving average of kr8.73.
Volatility
CONTEXTVISION’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.16%, a negative 0.01%, and a positive 1.72%.
CONTEXTVISION’s highest amplitude of average volatility was 1.74% (last week), 1.39% (last month), and 1.72% (last quarter).
Sales Growth
CONTEXTVISION’s sales growth for the current quarter is 29.2%.
More news about CONTEXTVISION.
2. EQUASENS (EQS.PA)
1.4% Forward Dividend Yield and 28.59% Return On Equity
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
Earnings Per Share
As for profitability, EQUASENS has a trailing twelve months EPS of €3.05.
PE Ratio
EQUASENS has a trailing twelve months price to earnings ratio of 24.89. Meaning, the purchaser of the share is investing €24.89 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.59%.
Volume
Today’s last reported volume for EQUASENS is 2520 which is 33.12% below its average volume of 3768.
Moving Average
EQUASENS’s worth is below its 50-day moving average of €81.22 and below its 200-day moving average of €76.24.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jul 3, 2023, the estimated forward annual dividend rate is 1.15 and the estimated forward annual dividend yield is 1.4%.
More news about EQUASENS.
3. BIOMERIEUX (BIM.PA)
0.89% Forward Dividend Yield and 12.95% Return On Equity
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings Per Share
As for profitability, BIOMERIEUX has a trailing twelve months EPS of €3.82.
PE Ratio
BIOMERIEUX has a trailing twelve months price to earnings ratio of 24.53. Meaning, the purchaser of the share is investing €24.53 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.95%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 6, 2023, the estimated forward annual dividend rate is 0.85 and the estimated forward annual dividend yield is 0.89%.
Volatility
BIOMERIEUX’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.02%, a negative 0.02%, and a positive 1.17%.
BIOMERIEUX’s highest amplitude of average volatility was 1.21% (last week), 0.89% (last month), and 1.17% (last quarter).
More news about BIOMERIEUX.
